Mark Wainberg, Ph.D.

The 8th International Congress on Drug Therapy in HIV Infection, held in Glasgow, Scotland, offered up considerable new information on antiretroviral chemotherapy. One important study conducted by Josep Mallolas and colleagues in Barcelona, Spain, de...

Fosamprenavir (FPV, 908, Lexiva, Telzir) is a potent protease inhibitor that was approved by the Food and Drug Administration in October 2003. Several studies have documented the safety and efficacy of once-daily fosamprenavir boosted with ritonavir ...

HIV has a remarkable ability to adapt to its surroundings. Thanks to its error-prone replication, the virus can develop mutations that confer a growth advantage in certain situations, such as in the presence of antiretroviral therapy. Although the fi...

HIV drug resistance is a growing problem with all antiretrovirals, so there is a great deal of interest in new drugs that may retain activity against mutations associated with resistance. The current study by Cal Cohen, of the Community Research Init...

How safe are antiretroviral nucleosides in HIV-infected individuals who are coinfected with hepatitis B or hepatitis C? The question is an important one, because of two reasons: Firstly, up to one third of people with HIV are coinfected with hepatiti...

In the beginning, there was zidovudine (AZT, Retrovir). As the first antiretroviral drug approved for the treatment of HIV, its benefits during the early years of the epidemic were incalculable. However, zidovudine's use also had at least one downsid...

Pathogenic Mechanisms of HIV Diseases: The Multifaceted Effects of Virus Replication and Viremia on the Host (Plenary Lecture 119) Presented by A. Fauci View the original abstract

In this presentation Dr. Fauci gave an overview of the path...

A Population Based-Analysis of Amprenavir Trough Concentrations Authored by Kurowski M., Sternfeld T., and Sawyer A.W. Poster P187

The subject of therapeutic drug monitoring (TDM) has assumed increased importance in HIV patient management,...